Sustained imatinib treatment in chronic myeloid leukemia patients can result in complete
molecular response allowing discontinuation without relapse. We set out to evaluate the …

Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the
randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition …

The objective of this prospective clinical trial (JALSG-STIM213, UMIN000011971) was to
evaluate treatment-free remission (TFR) rates after discontinuation of imatinib in chronic …

Background Tyrosine kinase inhibitors treatment in responding chronic myeloid leukaemia
(CML) patients is generally continued indefinitely. In this randomised phase II trial, we …

Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and
400 mg/day is considered the standard dose. Although it is generally well tolerated, some …

Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …

Abstract Abstract 859 Background Imatinib (IM) has greatly improved survival rates in
chronic myeloid leukemia*(* CML). However, all patients (pts) must continue treatment for an …

Tyrosine kinase inhibitors (TKI) have dramatically changed the management and the
outcome of chronic myeloid leukemia (CML) patients. Imatinib is recognized as gold …

Abstract Abstract 360 Introduction: The lack of a sufficient response to first line imatinib
treatment has been observed in a substantial proportion of CML patients and has been …

The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in
chronic myeloid leukemia patients who were initially treated with IM and achieved complete …